CL2012000185A1 - Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer. - Google Patents

Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer.

Info

Publication number: CL2012000185A1
Authority: CL; Chile
Prior art keywords: treatment; oxazine; oxazepine; alzheimer; disease
Prior art date: 2009-07-24

Application number

CL2012000185A

Other languages

English (en)

Spanish (es)

Inventor

Konstanze Hurth

Philipp Holzer

Mathias Frederiksen

Rainer Martin Lueoend

Sangamesh Badiger

Murali Chebrolu

Machaue

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-24

Filing date

2012-01-23

Publication date

2012-10-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42629546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-01-23 Application filed by Novartis Ag filed Critical Novartis Ag

2012-10-12 Publication of CL2012000185A1 publication Critical patent/CL2012000185A1/es

Links

BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 title 1
208000003808 Amyloid Neuropathies Diseases 0.000 title 1
101150058765 BACE1 gene Proteins 0.000 title 1
208000028698 Cognitive impairment Diseases 0.000 title 1
208000010877 cognitive disease Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
238000009825 accumulation Methods 0.000 abstract 1
230000000926 neurological effect Effects 0.000 abstract 1
150000004893 oxazines Chemical class 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2012000185A 2009-07-24 2012-01-23 Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer. CL2012000185A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US22847209P	2009-07-24	2009-07-24
US25891109P	2009-11-06	2009-11-06
US36370210P	2010-07-13	2010-07-13

Publications (1)

Publication Number	Publication Date
CL2012000185A1 true CL2012000185A1 (es)	2012-10-12

Family

ID=42629546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012000185A CL2012000185A1 (es)	2009-07-24	2012-01-23	Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer.

Country Status (26)

Country	Link
US (5)	US8207164B2 (fr)
EP (1)	EP2456763B1 (fr)
JP (1)	JP5767214B2 (fr)
KR (2)	KR20140004810A (fr)
CN (1)	CN102471293B (fr)
AR (1)	AR077328A1 (fr)
AU (1)	AU2010274913B2 (fr)
CA (1)	CA2768980A1 (fr)
CL (1)	CL2012000185A1 (fr)
CO (1)	CO6491058A2 (fr)
CR (1)	CR20120002A (fr)
CU (1)	CU24083B1 (fr)
EA (1)	EA201200174A1 (fr)
EC (1)	ECSP12011622A (fr)
ES (1)	ES2534315T3 (fr)
GT (1)	GT201200016A (fr)
IL (1)	IL217378A (fr)
MA (1)	MA33450B1 (fr)
MX (1)	MX2012001070A (fr)
NZ (1)	NZ597529A (fr)
PE (1)	PE20121440A1 (fr)
SG (1)	SG177397A1 (fr)
TW (1)	TW201107316A (fr)
UY (1)	UY32799A (fr)
WO (1)	WO2011009943A1 (fr)
ZA (1)	ZA201200155B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
CN101346357B (zh)	2005-10-25	2014-04-02	盐野义制药株式会社	氨基二氢噻嗪衍生物
JP5383483B2 (ja)	2007-04-24	2014-01-08	塩野義製薬株式会社	アルツハイマー症治療用医薬組成物
EP2689780A1 (fr)	2007-04-24	2014-01-29	Shionogi & Co., Ltd.	Intermédiaires de dérivés d'aminodihydrothiazine substitués avec un groupe cyclique
KR101324426B1 (ko)	2008-06-13	2013-10-31	시오노기세야쿠 가부시키가이샤	β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CN102186841A (zh)	2008-10-22	2011-09-14	盐野义制药株式会社	具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
UY32799A (es)	2009-07-24	2011-02-28	Novartis Ag	Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en)	2009-08-19	2012-05-29	Hoffman-La Roche Inc.	3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
EP2485920B1 (fr)	2009-10-08	2016-04-27	Merck Sharp & Dohme Corp.	Composés hétérocycliques iminopentafluorosoufrés en tant qu'inhibiteurs de bace-1, compositions et leur utilisation
EP2485591B1 (fr)	2009-10-08	2016-03-23	Merck Sharp & Dohme Corp.	Composés de type dioxyde d'imino-thiadiazine utilisés en tant qu'inhibiteurs de bace, compositions en contenant et leur utilisation
US8557826B2 (en)	2009-10-08	2013-10-15	Merck Sharp & Dohme Corp.	Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
UA108363C2 (uk)	2009-10-08	2015-04-27		Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
KR20120104570A (ko)	2009-12-11	2012-09-21	시오노기세야쿠 가부시키가이샤	옥사진 유도체
UA103272C2 (uk)	2009-12-11	2013-09-25	Ф. Хоффманн-Ля Рош Аг	2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US20120277244A1 (en) *	2009-12-31	2012-11-01	Novartis Ag	Pyrazine derivatives and their use in the treatment of neurological disorders
JP5584352B2 (ja)	2010-03-15	2014-09-03	アムジエン・インコーポレーテツド	β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
US8673894B2 (en) *	2010-05-07	2014-03-18	Hoffmann-La Roche Inc.	2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
KR101730937B1 (ko) *	2010-06-09	2017-04-27	얀센 파마슈티카 엔.브이.	베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체
BR112012004154A2 (pt) *	2010-07-13	2017-05-30	Novartis Ag	"derivados de oxazina e seu uso no tratamento de distúrbios neurológicos"
CN103261199A (zh)	2010-10-29	2013-08-21	盐野义制药株式会社	萘啶衍生物
EP2634188A4 (fr)	2010-10-29	2014-05-07	Shionogi & Co	Dérivé d'aminodihydropyrimidine fusionnée
BR112013015430A2 (pt)	2010-12-22	2016-09-20	Janssen Pharmaceutica Nv	derivados de 5,6-diidro-imidazo[1,2-a]pirazin-8-ilamina úteis como inibidores de beta-secretase (bace)
US8524897B2 (en) *	2011-01-12	2013-09-03	Novartis Ag	Crystalline oxazine derivative
KR20140051822A (ko) *	2011-01-12	2014-05-02	노파르티스 아게	옥사진 유도체 및 신경계 장애의 치료에서의 그의 용도
CN103596569A (zh) *	2011-01-13	2014-02-19	诺瓦提斯公司	用于治疗代谢障碍的bace-2抑制剂
DK2663561T3 (en)	2011-01-13	2016-06-06	Novartis Ag	New heterocyclic derivatives and their use in treating neurological disorders
US9242943B2 (en) *	2011-01-18	2016-01-26	Siena Biotech S.P.A.	1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8399459B2 (en) *	2011-02-02	2013-03-19	Hoffmann-La Roche Inc.	1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8815841B2 (en)	2011-02-18	2014-08-26	Hoffmann-La Roche Inc.	1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
CN103415519B (zh) *	2011-03-01	2016-03-02	詹森药业有限公司	作为β-分泌酶(BACE)抑制剂有用的6，7-二氢-吡唑[1，5-a]吡嗪-4-基胺衍生物
US9067924B2 (en) *	2011-03-04	2015-06-30	Hoffmann-La Roche Inc.	1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
PH12013501805A1 (en)	2011-03-09	2013-11-18	Janssen Pharmaceutica Nv	3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
US8748418B2 (en) *	2011-03-18	2014-06-10	Hoffmann-La Roche Inc.	1,4-oxazepines as BACE1 and/or BACE2 inhibitors
US8877744B2 (en)	2011-04-04	2014-11-04	Hoffmann-La Roche Inc.	1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
EP2694489B1 (fr)	2011-04-07	2017-09-06	Merck Sharp & Dohme Corp.	Composés de dioxyde de thiadiazine condensés avec des dérivés oxacycliques en c5-c6 comme inhibiteurs de bace, compositions, et utilisation use
US9145426B2 (en)	2011-04-07	2015-09-29	Merck Sharp & Dohme Corp.	Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8754075B2 (en)	2011-04-11	2014-06-17	Hoffmann-La Roche Inc.	1,3-oxazines as BACE1 and/or BACE2 inhibitors
RU2013150349A (ru)	2011-04-13	2015-05-20	Мерк Шарп И Доум Корп.	5-замещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов васе, содержащие их композиции и их применение
CN103608345A (zh)	2011-04-26	2014-02-26	盐野义制药株式会社	噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
US9079919B2 (en) *	2011-05-27	2015-07-14	Hoffmann-La Roche Inc.	Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
AU2012266544A1 (en) *	2011-06-07	2013-11-21	F. Hoffmann-La Roche Ag	Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
MX2013014007A (es) *	2011-06-07	2014-03-12	Hoffmann La Roche	[1,3] oxazinas.
US8927535B2 (en) *	2011-07-06	2015-01-06	Hoffman-La Roche Inc.	Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
US9181236B2 (en)	2011-08-22	2015-11-10	Merck Sharp & Dohme Corp.	2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
JP2014526560A (ja)	2011-09-21	2014-10-06	アムジエン・インコーポレーテツド	β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
EP2766358B1 (fr) *	2011-10-13	2016-06-22	Novartis AG	Dérivés de l'oxazine et leur utilisation pour le traitement d'une maladie
UA111749C2 (uk)	2011-12-05	2016-06-10	Янссен Фармацевтика Нв	Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну
CA2853891C (fr) *	2011-12-06	2020-03-10	Janssen Pharmaceutica Nv	Derives de 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine
PE20142376A1 (es) *	2012-01-26	2015-01-17	Hoffmann La Roche	Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
US8338413B1 (en)	2012-03-07	2012-12-25	Novartis Ag	Oxazine derivatives and their use in the treatment of neurological disorders
WO2014059185A1 (fr) *	2012-10-12	2014-04-17	Amgen Inc.	Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation
WO2014065434A1 (fr)	2012-10-24	2014-05-01	Shionogi & Co., Ltd.	Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
WO2014078314A1 (fr)	2012-11-15	2014-05-22	Amgen Inc.	Composés d'amino-oxazine et d'amino-dihydrothiazine jouant le rôle de modulateurs de bêta-sécrétase et procédés d'utilisation
AU2013363151A1 (en)	2012-12-20	2015-06-04	Merck Sharp & Dohme Corp.	C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
US9751886B2 (en)	2013-06-12	2017-09-05	Janssen Pharmaceutica Nv	4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
WO2014198851A1 (fr)	2013-06-12	2014-12-18	Janssen Pharmaceutica Nv	Dérivés de 4-amino-6-phényl-5,6-dihydro-imidazo[1,5-a]pyrazin-3(2h)-one utilisés comme inhibiteurs de la bêta-sécrétase (bace)
CN105283457B (zh)	2013-06-12	2018-09-18	詹森药业有限公司	作为β-分泌酶(BACE)抑制剂的4-氨基-6-苯基-5,6-二氢咪唑并[1,5-A]吡嗪衍生物
FR3025591B1 (fr) *	2014-09-05	2016-10-14	Technofan	Dispositif de ventilation, aeronef comportant un tel dispositif de ventilation et procede de surveillance associe
ES2768823T3 (es)	2014-12-18	2020-06-23	Janssen Pharmaceutica Nv	Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
TW201726651A (zh) *	2015-09-23	2017-08-01	健生藥品公司	２，３，４，５－四氫吡啶－６－胺衍生物
US10399995B2 (en)	2016-08-26	2019-09-03	Eli Lilly And Company	1,4-Oxazines useful as selective BACE1 inhibitors
US10159191B2 (en)	2016-09-23	2018-12-25	Deere & Company	Harvester grain unloader
CN110018266B (zh) *	2019-02-15	2022-03-04	广州市妇女儿童医疗中心	一种快速定量分析48种氨基酸的方法
CN112250580A (zh) *	2020-10-28	2021-01-22	上海昂卓新材料科技有限公司	一种2-硝基-2-取代苯基丙烷-1,3-二醇的制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL6911868A (fr)	1968-08-31	1970-03-03
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
TW385308B (en) *	1994-03-04	2000-03-21	Merck & Co Inc	Prodrugs of morpholine tachykinin receptor antagonists
TW200502221A (en) *	2002-10-03	2005-01-16	Astrazeneca Ab	Novel lactams and uses thereof
CA2514733A1 (fr)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Compositions pharmaceutiques a base d'un co-cristal
TW200505902A (en) *	2003-03-20	2005-02-16	Schering Corp	Cannabinoid receptor ligands
JP4707560B2 (ja)	2003-12-29	2011-06-22	Ｍｓｄ株式会社	新規２−ヘテロアリール置換ベンズイミダゾール誘導体
JP2007524682A (ja)	2004-02-12	2007-08-30	メルク　エンド　カムパニー　インコーポレーテッド	代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
SV2006002232A (es)	2004-09-21	2006-05-25	Lilly Co Eli	Inhibidores bace ref. x-16940
US7888374B2 (en) *	2005-01-28	2011-02-15	Abbott Laboratories	Inhibitors of c-jun N-terminal kinases
CN101346357B (zh) *	2005-10-25	2014-04-02	盐野义制药株式会社	氨基二氢噻嗪衍生物
ES2431163T3 (es)	2007-03-01	2013-11-25	Novartis Ag	Inhibidores de PIM quinasa y métodos para su uso
JP5383483B2 (ja)	2007-04-24	2014-01-08	塩野義製薬株式会社	アルツハイマー症治療用医薬組成物
EP2689780A1 (fr)	2007-04-24	2014-01-29	Shionogi & Co., Ltd.	Intermédiaires de dérivés d'aminodihydrothiazine substitués avec un groupe cyclique
GB0713686D0 (en)	2007-07-13	2007-08-22	Addex Pharmaceuticals Sa	New compounds 2
BRPI0906962B8 (pt)	2008-01-18	2021-05-25	Eisai R&D Man Co Ltd	composto de aminodiidrotiazina fundido
US20100197688A1 (en) *	2008-05-29	2010-08-05	Nantermet Philippe G	Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
KR101324426B1 (ko)	2008-06-13	2013-10-31	시오노기세야쿠 가부시키가이샤	β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
TW201028381A (en)	2008-07-14	2010-08-01	Shionogi & Co	Pyridine derivative having ttk inhibition activity
CN102186841A (zh)	2008-10-22	2011-09-14	盐野义制药株式会社	具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
US9237972B2 (en)	2008-12-16	2016-01-19	Kimberly-Clark Worldwide, Inc.	Liquid surfactant compositions that adhere to surfaces and solidify and swell in the presence of water and articles using the same
US8461160B2 (en)	2009-05-08	2013-06-11	Hoffmann-La Roche, Inc.	Dihydropyrimidinones
UY32799A (es)	2009-07-24	2011-02-28	Novartis Ag	Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en)	2009-08-19	2012-05-29	Hoffman-La Roche Inc.	3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
CN102686584A (zh)	2009-11-13	2012-09-19	盐野义制药株式会社	具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物
US7964594B1 (en)	2009-12-10	2011-06-21	Hoffmann-La Roche Inc.	Amino oxazine derivatives
UA103272C2 (uk)	2009-12-11	2013-09-25	Ф. Хоффманн-Ля Рош Аг	2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
KR20120104570A (ko)	2009-12-11	2012-09-21	시오노기세야쿠 가부시키가이샤	옥사진 유도체
US8673894B2 (en)	2010-05-07	2014-03-18	Hoffmann-La Roche Inc.	2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
KR101730937B1 (ko)	2010-06-09	2017-04-27	얀센 파마슈티카 엔.브이.	베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체
ES2459593T3 (es)	2010-06-09	2014-05-09	Janssen Pharmaceutica, N.V.	Derivados de 5-amino-3,6-dihidro-1H-pirazin-2-ona útiles como inhibidores de beta-secretasa (BACE)
BR112012004154A2 (pt) *	2010-07-13	2017-05-30	Novartis Ag	"derivados de oxazina e seu uso no tratamento de distúrbios neurológicos"
US8524897B2 (en)	2011-01-12	2013-09-03	Novartis Ag	Crystalline oxazine derivative
KR20140051822A (ko)	2011-01-12	2014-05-02	노파르티스 아게	옥사진 유도체 및 신경계 장애의 치료에서의 그의 용도
CN103596569A (zh)	2011-01-13	2014-02-19	诺瓦提斯公司	用于治疗代谢障碍的bace-2抑制剂
DK2663561T3 (en)	2011-01-13	2016-06-06	Novartis Ag	New heterocyclic derivatives and their use in treating neurological disorders
EP2766358B1 (fr)	2011-10-13	2016-06-22	Novartis AG	Dérivés de l'oxazine et leur utilisation pour le traitement d'une maladie

2010
- 2010-07-22 UY UY0001032799A patent/UY32799A/es not_active Application Discontinuation
- 2010-07-22 AR ARP100102667A patent/AR077328A1/es unknown
- 2010-07-23 KR KR1020137033812A patent/KR20140004810A/ko not_active Withdrawn
- 2010-07-23 NZ NZ597529A patent/NZ597529A/xx not_active IP Right Cessation
- 2010-07-23 EA EA201200174A patent/EA201200174A1/ru unknown
- 2010-07-23 PE PE2012000094A patent/PE20121440A1/es not_active Application Discontinuation
- 2010-07-23 JP JP2012521053A patent/JP5767214B2/ja not_active Expired - Fee Related
- 2010-07-23 TW TW099124438A patent/TW201107316A/zh unknown
- 2010-07-23 KR KR1020127001651A patent/KR101422965B1/ko not_active Expired - Fee Related
- 2010-07-23 SG SG2011096823A patent/SG177397A1/en unknown
- 2010-07-23 CN CN201080035169.0A patent/CN102471293B/zh not_active Expired - Fee Related
- 2010-07-23 US US12/842,360 patent/US8207164B2/en active Active
- 2010-07-23 MA MA34558A patent/MA33450B1/fr unknown
- 2010-07-23 AU AU2010274913A patent/AU2010274913B2/en not_active Ceased
- 2010-07-23 EP EP10737870.5A patent/EP2456763B1/fr not_active Revoked
- 2010-07-23 MX MX2012001070A patent/MX2012001070A/es active IP Right Grant
- 2010-07-23 WO PCT/EP2010/060718 patent/WO2011009943A1/fr not_active Ceased
- 2010-07-23 CU CU2012000013A patent/CU24083B1/es not_active IP Right Cessation
- 2010-07-23 CA CA2768980A patent/CA2768980A1/fr not_active Abandoned
- 2010-07-23 ES ES10737870.5T patent/ES2534315T3/es active Active
2012
- 2012-01-05 IL IL217378A patent/IL217378A/en not_active IP Right Cessation
- 2012-01-09 ZA ZA2012/00155A patent/ZA201200155B/en unknown
- 2012-01-09 CR CR20120002A patent/CR20120002A/es unknown
- 2012-01-19 CO CO12007858A patent/CO6491058A2/es active IP Right Grant
- 2012-01-23 CL CL2012000185A patent/CL2012000185A1/es unknown
- 2012-01-24 GT GT201200016A patent/GT201200016A/es unknown
- 2012-01-24 EC EC2012011622A patent/ECSP12011622A/es unknown
- 2012-04-24 US US13/454,751 patent/US20120238560A1/en not_active Abandoned
2013
- 2013-07-12 US US13/940,354 patent/US20140088084A1/en not_active Abandoned
- 2013-12-20 US US14/136,679 patent/US8846658B2/en active Active
2014
- 2014-07-07 US US14/324,883 patent/US20150018338A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN102471293A (zh)	2012-05-23
ES2534315T3 (es)	2015-04-21
ZA201200155B (en)	2012-09-26
CU24083B1 (es)	2015-03-30
KR20120039655A (ko)	2012-04-25
MX2012001070A (es)	2012-03-16
EP2456763A1 (fr)	2012-05-30
HK1166314A1 (en)	2012-10-26
AU2010274913A1 (en)	2012-02-02
PE20121440A1 (es)	2012-11-06
US20110021520A1 (en)	2011-01-27
ECSP12011622A (es)	2012-02-29
UY32799A (es)	2011-02-28
US8846658B2 (en)	2014-09-30
US8207164B2 (en)	2012-06-26
NZ597529A (en)	2013-11-29
IL217378A (en)	2015-02-26
IL217378A0 (en)	2012-03-01
US20140113894A1 (en)	2014-04-24
EA201200174A1 (ru)	2012-08-30
CO6491058A2 (es)	2012-07-31
US20120238560A1 (en)	2012-09-20
WO2011009943A1 (fr)	2011-01-27
GT201200016A (es)	2013-09-23
JP5767214B2 (ja)	2015-08-19
CU20120013A7 (es)	2012-04-15
AR077328A1 (es)	2011-08-17
KR101422965B1 (ko)	2014-07-23
TW201107316A (en)	2011-03-01
MA33450B1 (fr)	2012-07-03
CA2768980A1 (fr)	2011-01-27
JP2013500247A (ja)	2013-01-07
EP2456763B1 (fr)	2015-01-21
US20150018338A1 (en)	2015-01-15
US20140088084A1 (en)	2014-03-27
SG177397A1 (en)	2012-02-28
AU2010274913B2 (en)	2013-09-19
CN102471293B (zh)	2014-10-01
CR20120002A (es)	2012-02-15
KR20140004810A (ko)	2014-01-13

Publication	Publication Date	Title
CL2012000185A1 (es)	2012-10-12	Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer.
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2008003593A1 (es)	2010-01-04	Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2012001762A1 (es)	2012-12-21	Compuestos derivados de pirazina, con actividad inhibidora de bace; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de enfermedad de alzheimer o deterioro cognitivo leve.
CL2007001882A1 (es)	2008-02-08	Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2012002497A1 (es)	2013-03-22	Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2007001881A1 (es)	2008-02-08	Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CR11731A (es)	2011-06-08	Composiciones y procedimientos para su preparación y uso
ECSP12011857A (es)	2012-08-31	Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
CO6501189A2 (es)	2012-08-15	Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
UY31314A1 (es)	2009-03-31	Amidas heterociclicas y sus métodos de uso-976
CL2008002744A1 (es)	2009-05-22	Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2.
GT200900230A (es)	2011-11-29	4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2012001605A1 (es)	2012-10-05	Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
UY29899A1 (es)	2007-06-29	Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
UY32483A (es)	2010-10-29	Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
PA8784001A1 (es)	2009-02-09	Oxazolidinonas sustituidas y su uso
NI201300055A (es)	2014-03-07	Compuestos y su uso como inhibidores de bace
CL2013000380A1 (es)	2013-05-31	Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
CL2014001838A1 (es)	2014-11-07	Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
EA201291413A1 (ru)	2013-05-30	Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
GT200800187A (es)	2009-04-07	Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2008000641A1 (es)	2008-09-12	Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
UY31322A1 (es)	2009-04-30	Amidas heterocíclicas y sus métodos de uso-975
CL2008002809A1 (es)	2009-11-27	Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.